


Paritaprevir free base

Chemical Properties

CAS No. :	1221573-85-8
Formula:	C ₄₀ H ₄₃ N ₇ O ₇ S
Molecular Weight:	765.89
Appearance:	no data available
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	Paritaprevir free base (ABT-450) is an orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, and infection is associated with the development of hepatocellular carcinoma (HCC).
Targets(IC50)	HCV Protease
In vitro	Paritaprevir demonstrates in vitro antiviral activity against HCV GT1-4 and GT6 (EC50 range, 0.09 to 19 nM), with an EC50 of 0.09 nM against GT4a[2].

Solubility Information

Solubility	DMSO: 10 mg/mL (13.06 mM), Sonication is recommended. (< 1 mg/mL refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.3057 mL	6.5284 mL	13.0567 mL
5 mM	0.2611 mL	1.3057 mL	2.6113 mL
10 mM	0.1306 mL	0.6528 mL	1.3057 mL
50 mM	0.0261 mL	0.1306 mL	0.2611 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Smith, M., & Lim, A. (2015). Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. *Drug Design, Development And Therapy*, 6083. doi: 10.2147/dddt.s80226

Schnell G, et al. Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/ritonavir. *Antimicrob Agents Chemother*. 2015 Aug 17. pii: AAC.01229-15.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481